Autoimmune Cardiotoxicity of Cancer Immunotherapy

Trends in Immunology

Volumn 38, Issue 2, 2017, Pages 77-78

  Cheng, Feixiong ^a,b   Loscalzo, Joseph ^c  

^a NORTHEASTERN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardio oncology; immune checkpoint; immunotherapy.; ipilimumab; nivolumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CELLS; CLINICAL TRIAL (TOPIC); DRUG SURVEILLANCE PROGRAM; FREQUENCY; HUMAN; IMMUNE SYSTEM; MALIGNANT NEOPLASM; MEDICAL SOCIETY; METASTATIC MELANOMA; MYOCARDITIS; MYOSITIS; SHORT SURVEY; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; RISK;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; IMMUNOTHERAPY; MYOCARDITIS; NEOPLASMS; RISK;

EID: 85007420814     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.11.007     Document Type: Short Survey

References (10)

1. 1 Ledford, H., Cocktails for cancer with a measure of immunotherapy. Nature 532 (2016), 162–164.
2. 2 Mahoney, K.M., et al. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Dis. 14 (2015), 561–584.
3. 3 Caspi, R.R., Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 8 (2008), 970–976.
4. 4 Johnson, D.B., et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375 (2016), 1749–1755.
5. 5 Laubli, H., et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer, 3, 2015, 11.
6. 6 Moslehi, J.J., Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375 (2016), 1457–1467.
7. 7 Ledford, H., Cancer experts unveil wishlist for US government ‘moonshot’. Nature 537 (2016), 288–289.
8. 8 Meng, X., et al. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 13 (2016), 167–179.
9. 9 Antman, E.M., Loscalzo, J., Precision medicine in cardiology. Nat. Rev. Cardiol. 13 (2016), 591–602.
10. 10 Sharma, P., Allison, P.J., The future of immune checkpoint therapy. Science 348 (2015), 56–61.